Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The overall objective of the research project presented here is to assess the prevalence of fibromyalgia in patients being treated for ADHD, the prevalence of ADHD in patients being treated for fibromyalgia, and the neurobiological correlates of ADHD-fibromyalgia comorbidity.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Patients with fibromyalgia being treated for ADHD | Experimental |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Samples | Biological | Blood and urine samples including metabolomic analyses. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Percentage of patients with fibromyalgia among patients with ADHD and no prior methylphenidate treatment | Comparison of the observed prevalence of fibromyalgia (as assessed by the ACR diagnostic criteria) among patients with ADHD (as assessed by the DIVA-5 diagnostic interview) and no prior methylphenidate treatment versus the theoretical prevalence of fibromyalgia in the overall French population | Baseline |
| Measure | Description | Time Frame |
|---|---|---|
| Percentage of patients with fibromyalgia among patients with ADHD and a current methylphenidate treatment | Comparison of the observed prevalence of fibromyalgia (as assessed by the ACR diagnostic criteria) among patients with ADHD (as assessed by the DIVA-5 diagnostic interview) and a current methylphenidate treatment versus the theoretical prevalence of fibromyalgia in the French overall population |
Not provided
Inclusion Criteria:
For patients with fibromyalgia :
For patients with ADHD treated with methylphenidate
For patients with ADHD but not treated with methylphenidate
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Paul BRUNAULT | Contact | 02 18 37 05 81 | paul.brunault@univ-tours.fr |
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D001289 | Attention Deficit Disorder with Hyperactivity |
| D005356 | Fibromyalgia |
| D059350 | Chronic Pain |
| ID | Term |
|---|---|
| D019958 | Attention Deficit and Disruptive Behavior Disorders |
| D065886 | Neurodevelopmental Disorders |
| D001523 | Mental Disorders |
| D009135 | Muscular Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D012494 | Sampling Studies |
| D011795 | Surveys and Questionnaires |
| ID | Term |
|---|---|
| D016020 | Epidemiologic Study Characteristics |
| D004812 | Epidemiologic Methods |
| D008919 | Investigative Techniques |
| D017531 | Health Care Evaluation Mechanisms |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Questionnaires | Other | Completing self-assessment questionnaires |
|
| Sensitivity to mechanical pain | Other | Assessment of sensitivity to mechanical pain (by using the Von Frey monofilament test) |
|
| Baseline |
| Comparison of the levels of cytokines (specific biomarkers of inflammation), between patients with fibromyalgia without ADHD | Plasma and urine levels of different cytokines (IFN-gamma, IL-1B, IL-6, IL10, IL-13, IL-17, TNF-alpha), as assessed by metabolomic analyses (high-performance liquid chromatography) | Baseline |
| Comparison of the levels of cytokines (specific biomarkers of inflammation), between patients with ADHD without fibromyalgia | Plasma and urine levels of different cytokines (IFN-gamma, IL-1B, IL-6, IL10, IL-13, IL-17, TNF-alpha), as assessed by metabolomic analyses (high-performance liquid chromatography) | Baseline |
| Comparison of the levels of cytokines (specific biomarkers of inflammation), between patients with fibromyalgia with ADHD | Plasma and urine levels of different cytokines (IFN-gamma, IL-1B, IL-6, IL10, IL-13, IL-17, TNF-alpha), as assessed by metabolomic analyses (high-performance liquid chromatography) | Baseline |
| Comparison of the levels of neuro-inflammation biomarkers (i.e., tryptophane derivatives, short carbon chain fatty acids, lipidomic profile) between patients with fibromyalgia without ADHD, | Plasma and urine levels of tryptophane derivatives, short carbon chain fatty acids and lipidomic profile, as assessed by metabolomic analyses | Baseline |
| Comparison of the levels of neuro-inflammation biomarkers (i.e., tryptophane derivatives, short carbon chain fatty acids, lipidomic profile) between patients with ADHD without fibromyalgia | Plasma and urine levels of tryptophane derivatives, short carbon chain fatty acids and lipidomic profile, as assessed by metabolomic analyses | Baseline |
| Comparison of the levels of neuro-inflammation biomarkers (i.e., tryptophane derivatives, short carbon chain fatty acids, lipidomic profile) between patients with fibromyalgia with ADHD | Plasma and urine levels of tryptophane derivatives short carbon chain fatty acids and lipidomic profile, as assessed by metabolomic analyses | Baseline |
| Comparison of the levels of 500 biomarkers of neurotransmission between patients with fibromyalgia without ADHD | Plasma and urine levels of 500 different biomarkers of neurotransmission (e.g., dopaminergic, serotoninergic, noradrenegic), as assessed by metabolomic analyses (high-performance liquid chromatography) | Baseline |
| Comparison of the levels of 500 biomarkers of neurotransmission between patients with: ADHD without fibromyalgia | Plasma and urine levels of 500 different biomarkers of neurotransmission (e.g., dopaminergic, serotoninergic, noradrenegic), as assessed by metabolomic analyses (high-performance liquid chromatography) | Baseline |
| Comparison of the levels of 500 biomarkers of neurotransmission between patients with fibromyalgia with ADHD | Plasma and urine levels of 500 different biomarkers of neurotransmission (e.g., dopaminergic, serotoninergic, noradrenegic), as assessed by metabolomic analyses (high-performance liquid chromatography) | Baseline |
| D009140 | Musculoskeletal Diseases |
| D012216 | Rheumatic Diseases |
| D009468 | Neuromuscular Diseases |
| D009422 | Nervous System Diseases |
| D010146 | Pain |
| D009461 | Neurologic Manifestations |
| D012816 | Signs and Symptoms |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D011787 | Quality of Health Care |
| D017530 | Health Care Quality, Access, and Evaluation |
| D011634 | Public Health |
| D004778 | Environment and Public Health |
| D003625 | Data Collection |